Autosomal Dominant Polycystic Kidney Disease in the 1980's
Overview
Authors
Affiliations
Since it is one of the commonest hereditary diseases, causing serious illness in adulthood, autosomal dominant polycystic kidney disease (ADPKD) is a problem for both the affected families and for the health economy of the society. The current management of ADPKD is reviewed with emphasis on the development of predictive DNA analyses, the recently discovered genetic heterogeneity, and ethical perspectives. Insurance aspects are discussed, and the need for access to selective reproductive prevention as well as for improvement of conventional therapeutic measures is stressed.
Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease.
Gilbert R, Evans H, Olalekan K, Nagra A, Haq M, Griffiths M Pediatr Nephrol. 2017; 32(5):893-896.
PMID: 28194574 PMC: 5368203. DOI: 10.1007/s00467-017-3584-9.
Sabanis N, Paschou E, Gavriilaki E, Mourounoglou M, Vasileiou S Case Rep Nephrol. 2015; 2015:982575.
PMID: 26301109 PMC: 4537735. DOI: 10.1155/2015/982575.
Trujillano D, Bullich G, Ossowski S, Ballarin J, Torra R, Estivill X Mol Genet Genomic Med. 2014; 2(5):412-21.
PMID: 25333066 PMC: 4190876. DOI: 10.1002/mgg3.82.
Type of PKD1 mutation influences renal outcome in ADPKD.
Cornec-Le Gall E, Audrezet M, Chen J, Hourmant M, Morin M, Perrichot R J Am Soc Nephrol. 2013; 24(6):1006-13.
PMID: 23431072 PMC: 3665389. DOI: 10.1681/ASN.2012070650.
Genetic heterogeneity of polycystic kidney disease in Bulgaria.
Bogdanova N, Dworniczak B, Dragova D, Todorov V, Dimitrakov D, Kalinov K Hum Genet. 1995; 95(6):645-50.
PMID: 7789949 DOI: 10.1007/BF00209481.